Skip to main content
SpringerLink
Log in

Imaging Genomics

  • Chapter
  • First Online:
Glioma Imaging

  • 980 Accesses

Abstract

Imaging genomics studies the relationship of clinical imaging features with genomic/molecular characteristics and has great potential to improve the diagnosis, treatment planning, and monitoring of patients with glioblastoma (GBM). While still a relatively young field, imaging genomics has made significant progress over the past decade. Here, we review clinically relevant genomic and molecular features of GBM, briefly describe MRI techniques with utility in the evaluation of GBM, and provide an overview of imaging genomics applications in the development of biomarkers of molecular tumor characteristics. Lastly we discuss how this approach can be leveraged to improve characterization of entire tumors throughout a patient’s treatment course in a non-invasive manner.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Mazurowski MA. Radiogenomics: what it is and why it is important. J Am Coll Radiol. 2015;12(8):862–6.

    Article  PubMed  Google Scholar 

  2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  CAS  PubMed  Google Scholar 

  3. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Inda MM, Bonavia R, Seoane J. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 2014;6(1):226–39.

    Article  CAS  Google Scholar 

  5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–20.

    Article  PubMed  Google Scholar 

  6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8.

    Article  CAS  Google Scholar 

  8. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.

    Article  CAS  PubMed  Google Scholar 

  10. Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42–56.. e6

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013;1(2):112–22.

    Article  CAS  PubMed  Google Scholar 

  12. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper LA, Appin C, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res. 2013;19(18):4951–60.

    Article  CAS  PubMed  Google Scholar 

  13. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol. 2004;63(7):700–7.

    Article  CAS  PubMed  Google Scholar 

  14. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12(3):197–209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang J, Yan J, Liu B. Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 2017;403:224–30.

    Article  CAS  PubMed  Google Scholar 

  16. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol. 1998;57(7):684–9.

    Article  CAS  PubMed  Google Scholar 

  17. Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, et al. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Onco Targets Ther. 2016;9:3485–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.

    Article  CAS  PubMed  Google Scholar 

  19. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6(1):39–51.

    Article  CAS  PubMed  Google Scholar 

  20. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–72.

    Article  CAS  PubMed  Google Scholar 

  21. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150–4.

    Article  CAS  PubMed  Google Scholar 

  22. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013;13(5):345.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131(2):242–51.

    CAS  PubMed  Google Scholar 

  24. Zhao J, Ma W, Zhao H. Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis. Neuro-Oncology. 2014;16(1):103–12.

    Article  CAS  PubMed  Google Scholar 

  25. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31.

    Article  CAS  PubMed  Google Scholar 

  26. Koschmann C, Lowenstein PR, Castro MG. ATRX mutations and glioblastoma: impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol Cell Oncol. 2016;3(3):e1167158.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Nandakumar P, Mansouri A, Das S. The role of ATRX in glioma biology. Front Oncol. 2017;7:236.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann Surg Oncol. 2014;21(4):1337–44.

    Article  PubMed  Google Scholar 

  29. England B, Huang T, Karsy M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 2013;34(4):2063–74.

    Article  CAS  PubMed  Google Scholar 

  30. Chaurasia A, Park SH, Seo JW, Park CK. Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival. J Korean Med Sci. 2016;31(8):1208–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Strommer K, Hamou MF, Diggelmann H, de Tribolet N. Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas. Acta Neurochir. 1990;107(3–4):82–7.

    Article  CAS  PubMed  Google Scholar 

  33. Padfield E, Ellis HP, Kurian KM. Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 2015;5:5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kim J, Lee IH, Cho HJ, Park CK, Jung YS, Kim Y, et al. Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell. 2015;28(3):318–28.

    Article  CAS  PubMed  Google Scholar 

  35. Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017;49(4):594–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Levy SE, Myers RM. Advancements in next-generation sequencing. Annu Rev Genomics Hum Genet. 2016;17:95–115.

    Article  CAS  PubMed  Google Scholar 

  37. HrdlickovaR, ToloueM, TianB. RNA-Seq methods for transcriptome analysis. Wiley Interdiscip Rev RNA. 2017;8(1).

    Article  CAS  Google Scholar 

  38. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. KurdyukovS, BullockM. DNA methylation analysis: choosing the right method. Biology (Basel). 2016;5(1).

    Article  PubMed Central  CAS  Google Scholar 

  40. Shruthi BS, Vinodhkumar P, Selvamani M. Proteomics: a new perspective for cancer. Adv Biomed Res. 2016;5:67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. ElBanan MG, Amer AM, Zinn PO, Colen RR. Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology. Neuroimaging Clin N Am. 2015;25(1):141–53.

    Article  PubMed  Google Scholar 

  42. Mabray MC, Barajas RF Jr, Cha S. Modern brain tumor imaging. Brain Tumor Res Treat. 2015;3(1):8–23.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby JS, et al. Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features. Sci Data. 2017;4:170117.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Rios Velazquez E, Meier R, Dunn WD Jr, Alexander B, Wiest R, Bauer S, et al. Fully automatic GBM segmentation in the TCGA-GBM dataset: prognosis and correlation with VASARI features. Sci Rep. 2015;5:16822.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004;10(1 Pt 1):212–21.

    Article  CAS  PubMed  Google Scholar 

  46. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005;11(24 Pt 1):8600–5.

    Article  CAS  PubMed  Google Scholar 

  47. Van Meter T, Dumur C, Hafez N, Garrett C, Fillmore H, Broaddus WC. Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol. 2006;15(4):195–205.

    Article  PubMed  Google Scholar 

  48. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging. 2003;18(5):530–6.

    Article  PubMed  Google Scholar 

  49. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105(13):5213–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008;249(1):268–77.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Drabycz S, Roldan G, de Robles P, Adler D, McIntyre JB, Magliocco AM, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. NeuroImage. 2010;49(2):1398–405.

    Article  CAS  PubMed  Google Scholar 

  52. Barajas RF Jr, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, et al. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology. 2010;254(2):564–76.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Zinn PO, Mahajan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6(10):e25451.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, et al. A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012;7(8):e41522.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Colen R, Foster I, Gatenby R, Giger ME, Gillies R, Gutman D, et al. NCI workshop report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl Oncol. 2014;7(5):556–69.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Kickingereder P, Bonekamp D, Nowosielski M, Kratz A, Sill M, Burth S, et al. Radiogenomics of glioblastoma: machine learning-based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology. 2016;281(3):907–18.

    PubMed  Google Scholar 

  57. Liu X, Mangla R, Tian W, Qiu X, Li D, Walter KA, et al. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma. J Neuro-Oncol. 2017;135(3):553–60.

    Article  CAS  Google Scholar 

  58. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, et al. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. NeuroImage. 2012;59(2):908–16.

    Article  CAS  PubMed  Google Scholar 

  59. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013;34(3):533–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33(7):1349–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Moon WJ, Choi JW, Roh HG, Lim SD, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology. 2012;54(6):555–63.

    Article  PubMed  Google Scholar 

  62. Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, et al. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol. 2012;33(6):1059–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Tejada Neyra MA, Neuberger U, Reinhardt A, Brugnara G, Bonekamp D, Sill M, et al. Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. Neuro-Oncology. 2018;20(11):1517–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Hong EK, Choi SH, Shin DJ, Jo SW, Yoo RE, Kang KM, et al. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. Eur Radiol. 2018;28(10):4350–61.

    Article  PubMed  Google Scholar 

  66. Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology. 2017;19(1):109–17.

    Article  CAS  PubMed  Google Scholar 

  67. Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, et al. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: a multicentre study. Eur Radiol. 2018;28(9):3640–50.

    Article  PubMed  Google Scholar 

  68. Prasanna P, Patel J, Partovi S, Madabhushi A, Tiwari P. Radiomic features from the peritumoral brain parenchyma on treatment-naive multi-parametric MR imaging predict long versus short-term survival in glioblastoma multiforme: preliminary findings. Eur Radiol. 2017;27(10):4188–97.

    Article  PubMed  Google Scholar 

  69. Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology. 2017;19(1):128–37.

    Article  CAS  PubMed  Google Scholar 

  70. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, et al. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013;123(9):3659–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol. 2012;107(1):197–205.

    Article  CAS  Google Scholar 

  74. Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17:13.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Jamshidi N, Diehn M, Bredel M, Kuo MD. Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology. 2014;270(1):1–2.

    Article  PubMed  Google Scholar 

  76. Gevaert O, Mitchell LA, Achrol AS, Xu J, Echegaray S, Steinberg GK, et al. Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology. 2015;276(1):313.

    Article  PubMed  Google Scholar 

  77. Rao A, Manyam G, Rao G, Jain R. Integrative analysis of mRNA, microRNA, and protein correlates of relative cerebral blood volume values in GBM reveals the role for modulators of angiogenesis and tumor proliferation. Cancer Inform. 2016;15:29–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Colen RR, Wang J, Singh SK, Gutman DA, Zinn PO. Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death. Radiology. 2015;275(1):215–27.

    Article  PubMed  Google Scholar 

  79. Grossmann P, Gutman DA, Dunn WD Jr, Holder CA, Aerts HJ. Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. BMC Cancer. 2016;16:611.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Barajas RF Jr, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro-Oncology. 2012;14(7):942–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Barajas RF Jr, Hess CP, Phillips JJ, Von Morze CJ, Yu JP, Chang SM, et al. Super-resolution track density imaging of glioblastoma: histopathologic correlation. AJNR Am J Neuroradiol. 2013;34(7):1319–25.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Heiland DH, Simon-Gabriel CP, Demerath T, Haaker G, Pfeifer D, Kellner E, et al. Integrative diffusion-weighted imaging and radiogenomic network analysis of glioblastoma multiforme. Sci Rep. 2017;7:43523.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Smedley NF, Hsu W. Using deep neural networks for radiogenomic analysis. Proc IEEE Int Symp Biomed Imaging. 2018;2018:1529–33.

    PubMed  PubMed Central  Google Scholar 

  84. Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013;267(2):560–9.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro-Oncology. 2013;15(5):626–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2013;267(1):212–20.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Hirai T, Murakami R, Nakamura H, Kitajima M, Fukuoka H, Sasao A, et al. Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. 2008;29(8):1505–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Jajamovich GH, Valiathan CR, Cristescu R, Somayajula S. Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma. J Neuro-Oncol. 2016;129(2):289–300.

    Article  Google Scholar 

  89. Rathore S, Akbari H, Rozycki M, Abdullah KG, Nasrallah MP, Binder ZA, et al. Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1. Sci Rep. 2018;8(1):5087.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  90. Barajas RF Jr, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, et al. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. Clin Radiol. 2015;70(10):1087–95.

    Article  PubMed  Google Scholar 

  91. Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, et al. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep. 2018;8(1):7.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  92. Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, et al. Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget. 2017;8(60):101244–54.

    Article  PubMed  PubMed Central  Google Scholar 

  93. McConnell HL, Schwartz DL, Richardson BE, Woltjer RL, Muldoon LL, Neuwelt EA. Ferumoxytol nanoparticle uptake in brain during acute neuroinflammation is cell-specific. Nanomedicine. 2016;12(6):1535–42.

    Article  CAS  PubMed  Google Scholar 

  94. Toth GB, Varallyay CG, Horvath A, Bashir MR, Choyke PL, Daldrup-Link HE, et al. Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int. 2017;92(1):47–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Qian X, Tan H, Zhang J, Zhao W, Chan MD, Zhou X. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation. Med Phys. 2016;43(11):5889.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Rathore S, Bakas S, Pati S, Akbari H, Kalarot R, Sridharan P, et al. Brain cancer imaging phenomics toolkit (brain-CaPTk): an interactive platform for quantitative analysis of glioblastoma. Brainlesion (2017). 2018;10670:133–45.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Neurology, Blood-Brain Barrier Program, Oregon Health and Science University, Portland, OR, USA

    Cymon N. Kersch

  2. Departments of Radiology and Advanced Imaging, Research Center, Knight Cancer Institute, Translational Research Program, Oregon Health and Science University, Portland, OR, USA

    Ramon F. Barajas Jr.

Authors
  1. Cymon N. Kersch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ramon F. Barajas Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramon F. Barajas Jr. .

Editor information

Editors and Affiliations

  1. David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    Whitney B. Pope

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kersch, C.N., Barajas, R.F. (2020). Imaging Genomics. In: Pope, W. (eds) Glioma Imaging. Springer, Cham. https://doi.org/10.1007/978-3-030-27359-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27359-0_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27358-3

  • Online ISBN: 978-3-030-27359-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation